A molecule produced by the body from omega-3 fatty acids has been found to help treat and prevent respiratory stress in mice.

As part of an ongoing study into the anti-inflammatory benefits of a diet rich in certain types of fish, such as salmon, mackerel and anchovies, researchers at Brigham and Women's Hospital and Harvard Medical School have discovered that consumption of omega-3 could help protect against asthma and allergies.

Supported by the National Institute of Allergy and Infectious Diseases, the study identified that the metabolic product of an omega-3 fatty acid, Resolvin E1 (RvE1), has a key role in reducing inflammation of the airways in mice.

The researchers suggest that RvE1 helps resolve inflammation of airways "by dampening innate immune signals" that trigger it.

According to the study's authors, as previous research has linked increased intake of omega-3 fatty acids to a lower prevalence of asthma in humans, the findings provide an opportunity to investigate the role of RvE1 as a potential treatment for asthma.

The European Federation of Allergy and Airway Diseases Patients Association is holding its annual conference today until June 28th in Warsaw, Poland.

Attendees will discuss the latest knowledge and future treatments of allergy, asthma and COPD.

Register now to access our FREE educational library

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...